Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

IBUPROFEN 200 MG TABLET

IBUPROFEN
$0.0323per EA
OTC

Strength

200 mg/1

Manufacturer

Time-Cap Labs Inc.

NDC

49483060101

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

IBUPROFEN

Approval Type

Generic (ANDA)

FDA Application

ANDA091239

On Market Since

3/22/2016

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price History

1W

0.0%

1M

-1.7%

3M

-2.7%

6M

-12.7%

1Y

+1.2%

3Y

-1.2%

5Y

-2.5%

All

+17.1%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

MINIPRIN EC 81 MG TABLET
Generic
49483033010•Time-Cap Labs Inc.
$0.0118
per EA
MINIPRIN EC 81 MG TABLET
Generic
49483033012•Time-Cap Labs Inc.
$0.0118
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035203•Chain Drug Marketing Association
$0.0121
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035210•Chain Drug Marketing Association
$0.0121
per EA
ST. JOSEPH ASPIRIN EC 81 MG TB
Generic
69536018112•Foundation Consumer Healthcare LLC
$0.0139
per EA
ASPIRIN EC 81 MG TABLET
Generic
00536123441•Rugby Laboratories
$0.0147
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904675180•Major Pharmaceuticals
$0.0147
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904678370•Major Pharmaceuticals
$0.0147
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059848•AmerisourceBergen
$0.0147
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059887•AmerisourceBergen
$0.0147
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy